Their analysis revealed a prevalence rate of 2.2% among early onset breast cancer BRCA1/BRCA2 mutation negative patients, unselected for family history and 0.9% if there were no additional features indicative of LFS [30]. The gene discussed is BRCA2; the disease is breast carcinoma.